c174e0ae-4b0a-4170-9122-b7da8ec61eac
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 67
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.500
- INTERFERON_GAMMA_RESPONSE+0.480
- INTERFERON_ALPHA_RESPONSE+0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.440
- E2F_TARGETS+0.400
- ANGIOGENESIS+0.390
- MYC_TARGETS_V2+0.380
- INFLAMMATORY_RESPONSE+0.370
- TNFA_SIGNALING_VIA_NFKB+0.370
- IL6_JAK_STAT3_SIGNALING+0.310
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.230
- TGF_BETA_SIGNALING-0.210
- PROTEIN_SECRETION-0.110
- BILE_ACID_METABOLISM-0.090
- OXIDATIVE_PHOSPHORYLATION-0.070
- KRAS_SIGNALING_DN-0.060
- CHOLESTEROL_HOMEOSTASIS-0.050
- PEROXISOME-0.040
- NOTCH_SIGNALING-0.030
- MITOTIC_SPINDLE+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | b291037d-31f4-4303-95c9-7322950a45a7 | — | — | 0.908 |
| 2 | MNG256 | — | — | 0.887 |
| 3 | TCGA-UY-A78P-01A-12R-A36F-07 | — | — | 0.881 |
| 4 | 6e639239-cdae-4412-880f-ef813a956ff7 | — | — | 0.880 |
| 5 | TCGA-66-2765-01A-01R-0851-07 | — | cohortSQ1 | 0.871 |
| 6 | MDT-AP-1106 | Med | Medulloblastoma | 0.871 |
| 7 | TCGA-FD-A5C1-01A-11R-A28M-07 | — | — | 0.863 |
| 8 | SRR1516055 | — | — | 0.862 |
| 9 | TCGA-63-A5MT-01A-21R-A26W-07 | — | cohortSQ1 | 0.861 |
| 10 | TCGA-66-2744-01A-01R-0980-07 | — | cohortA1 | 0.860 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.480 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.460 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.440 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.390 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.380 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.370 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.290 | Idelalisib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.270 | Inavolisib | — uncovered |
| APOPTOSIS | 0.260 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| COAGULATION | 0.230 | Binimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.230 | Idelalisib | — uncovered |